- Home
- VRA vs PBYI Comparison
VRA vs PBYI Comparison
Compare VRA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRA
- PBYI
- Stock Information
- Founded
- VRA 1982
- PBYI 2010
- Country
- VRA United States
- PBYI United States
- Employees
- VRA N/A
- PBYI N/A
- Industry
- VRA Apparel
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- VRA Consumer Discretionary
- PBYI Health Care
- Exchange
- VRA Nasdaq
- PBYI Nasdaq
- Market Cap
- VRA 102.9M
- PBYI 153.2M
- IPO Year
- VRA 2010
- PBYI N/A
- Fundamental
- Price
- VRA $3.72
- PBYI $3.09
- Analyst Decision
- VRA Strong Buy
- PBYI Strong Buy
- Analyst Count
- VRA 1
- PBYI 1
- Target Price
- VRA $5.50
- PBYI $7.00
- AVG Volume (30 Days)
- VRA 363.1K
- PBYI 754.5K
- Earning Date
- VRA 12-11-2024
- PBYI 02-27-2025
- Dividend Yield
- VRA N/A
- PBYI N/A
- EPS Growth
- VRA N/A
- PBYI 492.79
- EPS
- VRA N/A
- PBYI 0.47
- Revenue
- VRA $405,268,000.00
- PBYI $243,569,000.00
- Revenue This Year
- VRA N/A
- PBYI N/A
- Revenue Next Year
- VRA $4.90
- PBYI N/A
- P/E Ratio
- VRA N/A
- PBYI $6.63
- Revenue Growth
- VRA N/A
- PBYI 6.30
- 52 Week Low
- VRA $3.27
- PBYI $2.23
- 52 Week High
- VRA $8.32
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- VRA 40.52
- PBYI 49.17
- Support Level
- VRA $3.46
- PBYI $2.92
- Resistance Level
- VRA $3.97
- PBYI $4.06
- Average True Range (ATR)
- VRA 0.22
- PBYI 0.29
- MACD
- VRA 0.05
- PBYI 0.01
- Stochastic Oscillator
- VRA 54.88
- PBYI 27.07
About VRA Vera Bradley Inc.
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.